BioCentury | Sep 16, 2020
Product Development

COVID-19 Quick Takes: secondary consequences of COVID-19 in children; plus BioNTech receives funding and expands trial, Regeneron enters RECOVERY, Valneva and Novavax

...treatment decisions such as the EUA for dexamethasone...
BioCentury | Sep 15, 2020
Product Development

Lilly’s Olumiant adds to remdesivir benefit in NIH COVID-19 study

...day 29 mortality as secondary endpoints; analyses of the survival data from ACTT-2 are under way.Dexamethasone...
...as it showed stronger effects in patients with more severe disease who required mechanical ventilation. Dexamethasone’s...
BioCentury | Sep 11, 2020
Product Development

Sept. 10 Quick Takes: approvals for Zai, GSK and Phase III readouts for Satsuma, Amryt and Takeda; plus Houston Methodist, MassBio and JPM

...in first-line multiple myelomaTakeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) said Ninlaro ixazomib plus lenalidomide and dexamethasone...
BioCentury | Sep 10, 2020
Product Development

Master protocols should not be a one-off phenomenon confined to COVID-19

...Data from RECOVERY supported the EUA of dexamethasone...
BioCentury | Sep 10, 2020
Product Development

U.S. needs master protocols such as U.K.’s RECOVERY to speed COVID-19 evidence collection, McClellan says: a BioCentury audio interview

...master protocol has, among other things, identified dexamethasone...
...come from that RECOVERY trial model -- dexamethasone...
BioCentury | Sep 9, 2020
Product Development

Back to School, behind the scenes: a BioCentury podcast

...and Oxford Univesity’s Martin Landray about how the U.K.’s RECOVERY master protocol trial, which identified dexamethasone...
BioCentury | Sep 9, 2020
Product Development

Networking that fueled COVID-19 response should spill into digital sciences and more, says Genmab’s van de Winkel: a BioCentury audio interview

...And we actually go to daratuma for one of the indications together with pomalidomide and dexamethasone...
BioCentury | Sep 7, 2020
Product Development

Bingham on U.K.’s flexible surge capacity in COVID-19 as foundation for future: a BioCentury audio interview

...first COVID-19 vaccine candidates to enter Phase III testing. The U.K. RECOVERY trial, which identified dexamethasone...
BioCentury | Sep 2, 2020
Product Development

EMA evaluating dexamethasone for COVID-19 as WHO meta-analysis of three steroids reiterates benefit

...Editor EMA includes RECOVERY data in review of dexamethasone MAAEMA said it has begun evaluating dexamethasone...
...data in its evaluation of the MAA. In June, data from the master protocol study’s dexamethasone...
...steroid reduced mortality, with the greatest effect seen in the sickest patients. The U.K. approved dexamethasone...
BioCentury | Sep 1, 2020
Product Development

Disease setting shields Vir, GSK trial of COVID-19 mAb from plasma EUA

...be complex regardless because of the use of Veklury remdesivir from Gilead Sciences Inc. (NASDAQ:GILD) and dexamethasone.Ethics...
Items per page:
1 - 10 of 1105